Bronchial asthma and allergic rhinitis frequently coexist. This study investigated correlations of health-related quality of life (QOL) questionnaires for these diseases, assessing whether the selective leukotriene receptor antagonist (LTRA), pranlukast, had additional benefits to overall asthma control when there was concomitant allergic rhinitis. Patients with asthma-associated allergic rhinitis were randomly allocated to either LTRA(+) (n = 21, treated for 3 months with pranlukast), or LTRA(-) (n = 8, no prankulast). At study start and at 3 months, pulmonary function was evaluated and QOL assessments were made using the Asthma Health Questionnaire-Japan (AHQ-Japan) and the Japan Rhino-conjunctivitis Quality of Life Questionnaire (JRQLQ). Total scores were significantly correlated both before and after therapy. After 3 months' therapy, pulmonary function and total AHQ-Japan and JRQLQ scores significantly improved in the LTRA(+) group, but not in the LTRA(-) group. A significant correlation between change at 3 months in the AHQ-Japan and JRQLQ scores from baseline values was seen in the LTRA(+) group. LTRA therapy improved allergic rhinitis symptoms, asthma symptoms and pulmonary function.
Introduction
The association between bronchial asthma and allergic rhinitis has recently been highlighted. These diseases are highly prevalent and often coexist: the prevalence of allergic rhinitis associated with asthma is estimated to be 10 -20%, 1, 2 and nearly 75% Y Ichimaru, H Kanazawa, H Kamoi et al.
Asthma with allergic rhinitis than normal subjects. 7 The diseases are related in epidemiological, anatomical, physiological, immunological and pharmacological terms. Since the nose, trachea and bronchus are continuous organs, the concept of 'one airway, one disease' was suggested in the Allergic Rhinitis and its Impact on Asthma (ARIA) 8 guidelines. For example, following nasal mucosa provocation with allergen, bronchial smooth-muscle constriction occurs and, in the lower airways, adhesion molecule expression and tissue eosinophilia are markedly increased. 9 -11 Traditionally, asthma and allergic rhinitis management has been separated into treatments for the upper and lower respiratory tracts. However, with illuminating new systems of nasobronchial cross-talk, 12 the 'one airway, one disease' hypothesis -which indicates that a therapeutic approach targeting one site may significantly improve another disease site -is being widely evaluated. This study sought to investigate the correlations of health-related quality of life (QOL) questionnaire results for asthma and allergic rhinitis, and to examine the effects of leukotriene receptor antagonist (LTRA) therapy on allergic rhinitis and asthma symptoms. If the 'one airway, one disease' hypothesis is correct, there may be an additional benefit to overall asthma when symptoms of allergic rhinitis are controlled.
Patients and methods

STUDY DESIGN AND TREATMENTS
This study was undertaken between February 2004 and April 2005, in asthma outpatients with allergic rhinitis attending The Osaka City University Hospital. The study was approved by the university hospital ethical committee and written informed consent was obtained from all patients. The patients were satisfied with the Global Initiative for Asthma (GINA) 2002 guidelines 13 and the ARIA rhinitis guidelines.
14 Eligible subjects were > 15 years of age, with a history of allergic rhinitis for ≥ 2 years. Patients had received daily asthma treatment for ≥ 3 months prior to the study. All were receiving inhaled corticosteroids (ICS) alone or ICS with non-steroidal asthma medications (i.e., short-acting or long-acting β 2 agonists, theophylline). Patients treated with oral or nasal corticosteroids and LTRA were excluded from the study. Patients received no other medications to control nasal symptoms for 4 weeks prior to, and during, the study.
ASSESSMENTS
Two health-related questionnaires were used: the Asthma Health Questionnaire-Japan (AHQ-Japan) 15 for asthma symptoms and the Japan Rhino-conjunctivitis Quality of Life Questionnaire (JRQLQ) 16 for allergic rhinitis symptoms. The AHQ-Japan consists of 32 questions and a face scale. All questions are evaluated on a scale from 0 to 4 and are categorized into six domains (asthma symptoms, factors that make asthma worse, emotion, activity, social activities, economy). The JRQLQ has six questions for rhinitis symptoms, eight for therapy, and 14 for psychogenic state, emotional factors, or medication compliance, etc. For both questionnaires a higher score indicates a worse QOL.
When patients were enrolled in the study, they answered both the AHQ-Japan and JRQLQ questionnaires and underwent pulmonary function tests. Patients were randomly allocated to two groups, in the ratio 2:1. The first group was treated with pranlukast (500 mg daily) in addition to previous therapy for three months 
STATISTICAL ANALYSIS
All results are expressed as mean ± SD. The Mann-Whitney U-test was used for intergroup comparisons, and Wilcoxon's signed-rank test was used to compare paired values. The significance of correlations was evaluated using Spearman's rankcorrelation coefficients. P-values < 0.05 were considered to be statistically significant.
Results
Thirty-four patients were enrolled in the study and allocated randomly to either the LTRA(+) group (n = 22) or the LTRA(-) group (n = 12). Five participants dropped out of the study, either because they refused to participate or they received nasal corticosteroids after enrolment. The results for 29 patients were therefore analysed (LTRA[+] group, n = 21 and LTRA [-] group, n = 8) and their clinical characteristics are shown in Table 1 . There were no significant differences between the two groups with respect to age, duration of asthma, airway hyper-responsiveness (provocative concentration of methacholine causing a 20% fall in FEV 1 ), baseline pulmonary function and asthma therapy.
Before LTRA therapy, the two total QOL scores (AHQ-Japan and JRQLQ) for all patients were significantly correlated (r = 0.63, P = 0.0003) (Fig. 1A ). After LTRA therapy there was also a significant 
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correlation between the two total scores (r = 0.55, P = 0.003) (Fig. 1B) . Total QOL scores for both the AHQ-Japan and JRQLQ were significantly improved in the LTRA(+) group (AHQ-Japan: pre 29.9 ± 3.6, post 24.9 ± 3.2, P = 0.002; JRQLQ: pre 23.5 ± 3.9, post 20.7 ± 4.0, P = 0.048), but they were not significantly improved in the LTRA(-) group (AHQ-Japan: pre 13.3 ± 3.3, post 13.6 ± 4.2; JRQLQ: pre 7.3 ± 1.8, post 7.4 ± 3.3) (Fig. 2) . After 3 months, mean changes in the AHQ-Japan and JRQLQ scores from baseline in the LTRA(+) group were -3.62 and -1.62, respectively, whilst in the LTRA(-) group they were 0.75 and 0.37, respectively (Fig. 3 ). In addition, there was a significant correlation of QOL change from baseline in the LTRA(+) group between the AHQ-Japan and JRQLQ (r = 0.42, P = 0.004).
Pulmonary function test results were also significantly improved in the LTRA(+) group (Fig. 4) .
Discussion
Our study identified a strong correlation between the results of the AHQ-Japan and JRQLQ in patients with asthma associated with allergic rhinitis. LTRA therapy significantly improved both QOL scores and had significant additional benefits for pulmonary function in these patients. Many studies have shown correlations between asthma and allergic rhinitis. 8, 17 In addition, several mechanisms could play a role in 
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lower airway dysfunction in patients with allergic rhinitis, including altered breathing pattern, pulmonary aspiration of nasal contents, the nasal-bronchial reflex and uptake of inflammatory mediators in the systemic circulation. In particular, concomitant histamine and leukotriene therapy is thought to aggravate both diseases. 18, 19 Indeed, the clinical efficacy of LTRA in relieving allergic rhinitis symptoms in patients with asthma has been documented previously. 20, 21 Good control of allergic rhinitis in those with co-morbid asthma reduced the risk of emergency room visits and hospitalizations due to severe asthma attacks, compared with patients whose allergic rhinitis was uncontrolled. 22 Lately, asthma and allergic rhinitis have been thought to be manifestations of one disease, with one affecting the other. 17, 23 Asthma symptoms improve when allergic rhinitis symptoms are well controlled, 22 and the systemic link between allergic rhinitis and asthma provides a rationale for systemic treatment. For example, treating the upper airway with LTRA or antihistamines is proven to control lower airway symptoms. 24 Thus, these systemic agents provide an additional therapeutic effect on asthma and may be important in inflammatory upper airway diseases. However, although accumulating evidence underlines the influence of nasal pathology on the control of asthma, both conditions are still treated as separate entities. Though few studies have investigated the effect of nasal treatment of asthma, research indicates that topical corticosteroid therapy reduces lower airway symptoms and decreases bronchial hypersensitivity in allergic rhinitis patients 25 -28 In our research, finding a good correlation between the two QOL studies suggests that the presence of allergic rhinitis worsens asthma symptoms. We therefore believe that not only allergic rhinitis symptoms, but also asthma symptoms, could be significantly improved following LTRA therapy. The present study clearly suggests that there is close interaction between the upper and lower airways. Our finding strongly indicates that nasal therapy may influence lower airway symptoms in asthmatic patients with concomitant upper airway pathology. However, the effect of nasal therapy on airway inflammation, especially small airway inflammation, is still unexplored. The observation that allergic rhinitis is ubiquitous in asthma and that both conditions are accompanied by airway inflammation, emphasizes the importance of undertaking further clinical trials in patients with concomitant asthma and allergic rhinitis. Moreover, the discrepancy between upper and lower airways remains unanswered. As the inflammatory pattern is very similar in nose and bronchi, it is still unclear which inflammatory factors are responsible for the development of central or peripheral airway inflammation. In fact, it is difficult to prove and analyse quantitatively for small airway inflammation in patients with allergic rhinitis. If the AHQ-Japan test reflects the degree of small airway inflammation in patients with asthma associated with allergic rhinitis, this measure will be more widely used in the investigation of the concept of 'one airway, one disease'. In future, we will be required to determine that our QOL method is useful for the evaluation of upper, lower, and even small airway inflammation in patients with allergic rhinitis associated with asthma.
